SCHEMBL17006012

SCHEMBL17006012

CC(CCCCO)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 1/20 0.44
LTA4H P09960 1/20 0.42
EPHX2 P34913 1/20 0.42
MAPT P10636 1/20 0.39
SLC1A3 P43003 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
RCE1 Q9Y256 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TRPA1 O75762 1/20 0.38
TSHR P16473 2/20 0.38
HDAC2 Q92769 1/20 0.37
HTT P42858 3/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17019229 1.00 RRM1 (0.44) RRM1LTA4HEPHX2MAPTSLC1A3
SCHEMBL31645502 1.00 RRM1 (0.44) RRM1LTA4HEPHX2MAPTSLC1A3
SCHEMBL2300063 0.95 LTA4H (0.44) RRM1LTA4HEPHX2MAPTSLC1A3
SCHEMBL6749224 0.87 SLC1A3 (0.42) MAPTSLC1A3SLC1A2SLC1A1MEN1
SCHEMBL4519983 0.87 SLC1A3 (0.42) MAPTSLC1A3SLC1A2SLC1A1MEN1
SCHEMBL22092032 0.87 SLC1A3 (0.42) MAPTSLC1A3SLC1A2SLC1A1MEN1
SCHEMBL10327182 0.87 LTA4H (0.39) RRM1LTA4HEPHX2MAPTSLC1A3
SCHEMBL6683665 0.84 ALDH1A1 (0.47) ALDH1A1TSHRMAPK1TDP1
SCHEMBL5722097 0.84 TRPA1 (0.38) MAPTSLC1A3SLC1A2SLC1A1MEN1
SCHEMBL4450876 0.84 TRPA1 (0.38) MAPTSLC1A3SLC1A2SLC1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107918-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-12-28 EP disclosed
US-9273067-B2 Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-01 US disclosed
WO-2015126737-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-27 WO disclosed
US-20150232481-A1 Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232481-A1 Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication TYMP, EIF2AK2, MAVS RRM1 105/4885LTA4H 3608/4885EPHX2 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.